4.4 Review

The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas

Journal

PATHOBIOLOGY
Volume 87, Issue 2, Pages 125-142

Publisher

KARGER
DOI: 10.1159/000507055

Keywords

Breast cancer; Immune cells; Tumor-infiltrating lymphocytes; Mutational load; Cancer-associated fibroblasts; Immunotherapy; Ligand 1 of programmed cell death protein 1

Funding

  1. Italian Ministry of Education, University and Research -MIUR [D15D18000410001, PRIN 2015HAJH8E]
  2. AIRC [22850]
  3. Fondazione Umberto Veronesi
  4. Dipartimenti di Eccellenza 2018-2022 [D15D18000410001]

Ask authors/readers for more resources

Heterogeneity in breast carcinomas can be appreciated at various levels, from morphology to molecular alterations, and there are well-known genotypic-phenotypic correlations. Clinical decision-making is strictly focused on the evaluation of tumor cells and is based on the assessment of hormone receptors and of the HER2 status, by means of a combination of immunohistochemical and in situ hybridization techniques. The tumor microenvironment (TME) also shows a multifaceted nature stemming from the different actors populating the intratumoral and the peritumoral stroma of breast carcinomas. Of note, we have now evidence that tumor-infiltrating lymphocytes (TILs) are clinically meaningful as their quantification in the intratumoral stroma strongly correlates with good prognosis, in particular in triple-negative and HER2-positive breast cancer patients. Nevertheless, TILs are just one of the many actors orchestrating the complexity of the TME, which is populated by immune and non-immune cells (cancer-associated fibroblasts, cancer-associated adipocytes), as well as non-cellular components such as chemical inflammation mediators. In this review article we will overview the main features of the distinct cell compartments by discussing (i) the potential impact the TME may have on the prognostic stratification of breast cancers and (ii) the possible predictive value of some markers in the context of immunotherapy in light of the recent results of phase III studies in advanced and early triple-negative breast cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available